<DOC>
	<DOCNO>NCT02809833</DOCNO>
	<brief_summary>This prospective , multicenter , non-interventional study enroll participant routine clinical practice Germany receive tocilizumab RA . The objective study systematic collection data use tocilizumab daily routine special emphasis treatment decision prescriber , compliance Summary Product Characteristics ( SmPC ) , documentation relevant activity score adverse drug reaction ( ADRs ) . The maximum observation period 12 month per participant .</brief_summary>
	<brief_title>Use Tocilizumab Rheumatoid Arthritis ( RA ) Daily Routine</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Moderate severe RA Tocilizumab indicate accordance SmPC chosen treat physician advance study None specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>